Decreased serum levels of TGF-β1 are associated with renal damage in female patients with systemic lupus erythematosus

Lupus

Volumn 21, Issue 3, 2012, Pages 310-318

  Jin, T ^a   Almehed, K ^a   Carlsten, H ^a   Forsblad D'Elia, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

glomerulonephritis; renal damage; SLEDAI; SLICC; systemic lupus erythematosus; TGF 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY INJURY; LEUKOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; TRANSFORMING GROWTH FACTOR BETA1 SERUM LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD SEDIMENTATION; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; PLATELET COUNT; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84856728656     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311425528     Document Type: Article

References (36)

1. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004 ; 29: 265-273
2. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998 ; 16: 137-161
3. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993 ; 90: 770-774 (Pubitemid 23028947)
4. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992 ; 359: 693-699
5. Yaswen L, Kulkarni AB, Fredrickson T, et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood. 1996 ; 87: 1439-1445 (Pubitemid 26056908)
6. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000 ; 12: 171-181 (Pubitemid 30398631)
7. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity. 2006 ; 25: 441-454 (Pubitemid 44354215)
8. Raz E, Dudler J, Lotz M, et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus. 1995 ; 4: 286-292
9. Jin YX, Xu LY, Guo H, Ishikawa M, Link H, Xiao BG. TGF-beta1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells. J Autoimmun. 2000 ; 14: 213-220
10. Piccirillo CA, Chang Y, Prud'homme GJ. TGF-beta1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol. 1998 ; 161: 3950-3956 (Pubitemid 28468971)
11. Chen W, Jin W, Cook M, Weiner HL, Wahl SM. Oral delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. J Immunol. 1998 ; 161: 6297-6304 (Pubitemid 28536005)
12. Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998 ; 160: 2539-2545 (Pubitemid 28119941)
13. Becker-Merok A, Eilertsen GO, Nossent JC. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J Rheumatol. 2010 ; 37: 2039-2045
14. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999 ; 10: 413-424 (Pubitemid 29068083)
15. Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009 ; 48: 542-545
16. Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford). 2007 ; 46: 1185-1190 (Pubitemid 47050627)
17. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277 (Pubitemid 13221242)
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
19. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 809-813 (Pubitemid 27199995)
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41
21. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999 ; 96: 319-328 (Pubitemid 29077586)
22. Xing Q, Wang B, Su H, Cui J, Li J. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int. 2011 ;:
23. Kohut E, Hajdu M, Gergely P, et al. Expression of TGFbeta1 and its signaling components by peripheral lymphocytes in systemic lupus erythematosus. Pathol Oncol Res. 2009 ; 15: 251-256
24. Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther. 2006 ; 8: R81 - R81
25. Stary G, Klein I, Bauer W, et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J Immunol. 2011 ; 186: 103-112
26. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005 ; 201: 1061-1067 (Pubitemid 40524674)
27. Huggins ML, Huang FP, Xu D, Lindop G, Stott DI. Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus. 1999 ; 8: 29-38 (Pubitemid 29050217)
28. Wang W, Huang XR, Li AG, et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol. 2005 ; 16: 1371-1383 (Pubitemid 41716521)
29. Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol. 2008 ; 19: 233-242 (Pubitemid 351240645)
30. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004 ; 15: 1-12 (Pubitemid 38020692)
31. O'Dell JR, Hays RC, Guggenheim SJ, Steigerwald JC. Tubulointerstitial renal disease in systemic lupus erythematosus. Arch Intern Med. 1985 ; 145: 1996-1999 (Pubitemid 16198398)
32. Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int. 2010 ; 77: 820-829
33. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest. 1996 ; 74: 991-1003 (Pubitemid 26182412)
34. Saxena V, Lienesch DW, Zhou M, et al. Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J Immunol. 2008 ; 180: 1903-1912
35. Onetti Muda A, Feriozzi S, Rahimi S, Faraggiana T. Expression of TGF-beta receptors type I and II in human glomerulonephritis. Nephrol Dial Transplant. 1998 ; 13: 279-284 (Pubitemid 28062185)
36. Yamamoto T, Watanabe T, Ikegaya N, et al. Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis. J Am Soc Nephrol. 1998 ; 9: 2253-2261 (Pubitemid 28543803)